Study on Talquetamab for People with Multiple Myeloma After BCMA CAR T-Cell Therapy

Inclusion Criteria

• Have multiple myeloma and have been treated with an IMID, PI, and a CD38 monoclonal antibody.
• Received BCMA CAR T-cell therapy ide-cel within 1-3 months before joining the study.
• Low levels of specific proteins in blood and urine tests.
• No signs of disease getting worse based on specific criteria.
• Aged 18 or older.
• Good overall health with a performance status of 0 or 1.
• Recovered from any side effects of previous treatments, except for mild nerve damage or hair loss.
• No ongoing symptoms from previous treatments like cytokine release syndrome or neurotoxicity.
• No additional myeloma treatments after CAR T-cell therapy.
• Adequate blood cell counts and organ function based on specific tests.
• Oxygen levels in the blood at or above 92%.
• Liver and kidney function within specified limits.
• Heart function with a pumping ability of 45% or more.
• Willing to follow the study schedule and requirements.
• Women of childbearing potential must use effective birth control and agree to pregnancy testing.
• Men must use condoms and agree not to donate sperm during and after the study.
• Must sign a consent form to participate.

Exclusion Criteria

• Previous treatment with GRPRC5D-directed therapy or T-cell redirection therapy within 3 months.
• Received an investigational vaccine (except COVID-19) or live vaccine within 4 weeks.
• Recent monoclonal antibody or cytotoxic therapy.
• Recent major surgery or plasmapheresis.
• Recent stem cell transplant or high-dose corticosteroids.
• History of organ transplant requiring immunosuppressive therapy.
• Recent significant bleeding or need for ongoing anticoagulant therapy.
• History of serious brain or nervous system conditions.
• Other active cancers or significant autoimmune diseases.
• Positive for HIV or active hepatitis infections.
• Recent cancer treatments with curative intent unless approved.
• Women who are pregnant, breastfeeding, or planning to become pregnant.
• Men planning to father a child during or after the study.
• Known allergies to study medications.
• Serious medical or psychiatric conditions affecting participation.
• Uncontrolled infections or lung disease requiring oxygen.
• Unwilling or unable to provide consent or attend follow-up visits.